OA11631A - Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor. - Google Patents

Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor. Download PDF

Info

Publication number
OA11631A
OA11631A OA9900295A OA9900295A OA11631A OA 11631 A OA11631 A OA 11631A OA 9900295 A OA9900295 A OA 9900295A OA 9900295 A OA9900295 A OA 9900295A OA 11631 A OA11631 A OA 11631A
Authority
OA
OAPI
Prior art keywords
compound
glucosidase inhibitor
insulin
composition according
pharmaceutically acceptable
Prior art date
Application number
OA9900295A
Other languages
English (en)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en
Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of OA11631A publication Critical patent/OA11631A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fodder In General (AREA)
OA9900295A 1997-06-18 1999-12-17 Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor. OA11631A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712865.6A GB9712865D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806708.5A GB9806708D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
OA11631A true OA11631A (en) 2004-11-22

Family

ID=26311746

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900295A OA11631A (en) 1997-06-18 1999-12-17 Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor.

Country Status (24)

Country Link
EP (1) EP0975343A1 (es)
JP (1) JP2001523271A (es)
KR (1) KR20010013845A (es)
CN (1) CN1274282A (es)
AP (1) AP9901720A0 (es)
AR (2) AR014881A1 (es)
AU (1) AU8799998A (es)
BG (1) BG103966A (es)
BR (1) BR9810186A (es)
CA (1) CA2294134A1 (es)
CO (1) CO4940453A1 (es)
DZ (1) DZ2519A1 (es)
EA (1) EA200000040A1 (es)
IL (1) IL133138A0 (es)
MA (1) MA26510A1 (es)
NO (1) NO996270L (es)
NZ (1) NZ501345A (es)
OA (1) OA11631A (es)
PE (1) PE89199A1 (es)
PL (1) PL337577A1 (es)
SK (1) SK179499A3 (es)
TR (1) TR199903072T2 (es)
UY (1) UY25051A1 (es)
WO (1) WO1998057635A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
HRP20010773B1 (en) 1999-04-23 2005-06-30 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
US20030045553A1 (en) 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
CN101121004B (zh) * 2006-08-08 2010-07-21 鲁南制药集团股份有限公司 含有胰岛素增敏剂和米格列醇的药物组合物
CN101584705B (zh) * 2008-05-24 2010-10-27 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物
CN101584688B (zh) * 2008-05-24 2010-11-10 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
JP2001523271A (ja) 2001-11-20
WO1998057635A1 (en) 1998-12-23
UY25051A1 (es) 2000-09-29
KR20010013845A (ko) 2001-02-26
NO996270D0 (no) 1999-12-17
SK179499A3 (en) 2000-11-07
CO4940453A1 (es) 2000-07-24
AR014881A1 (es) 2001-04-11
PL337577A1 (en) 2000-08-28
MA26510A1 (fr) 2004-12-20
EA200000040A1 (ru) 2000-08-28
IL133138A0 (en) 2001-03-19
CA2294134A1 (en) 1998-12-23
PE89199A1 (es) 1999-10-23
NZ501345A (en) 2001-10-26
EP0975343A1 (en) 2000-02-02
BR9810186A (pt) 2000-08-08
TR199903072T2 (xx) 2000-07-21
AR013352A1 (es) 2000-12-27
AU8799998A (en) 1999-01-04
BG103966A (bg) 2000-07-31
AP9901720A0 (en) 1999-12-31
DZ2519A1 (fr) 2003-02-01
NO996270L (no) 1999-12-17
CN1274282A (zh) 2000-11-22

Similar Documents

Publication Publication Date Title
OA11279A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide.
OA11517A (en) Treatment of diabetes with rosiglitazone and insulin.
OA11312A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor.
AU743269B2 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AU766928B2 (en) Combinations comprising a beta-agonist and a further antidiabetic agent
US20050054687A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
OA11510A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea.
SK179499A3 (en) The use of insulin sensitiser and alpha-glucosidase inhibitive antihyperglycaemic agent
US20040192737A1 (en) Use of thiazolidinediones for the treatment of hyperglycaemia
AP1223A (en) Use of thiazolidinediones for the treatment of hyperglycaemia.
US20020082284A1 (en) Use of thiazolidinediones for the treatment of hyperglycaemia
WO1999018943A1 (en) Use of thiazolidinediones for the treatment of hyperglycaemia
US20030073644A1 (en) Combinations comprising a beta-agonist and a further antidiabetic agent
AU4586902A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
AU4587002A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
ZA200103792B (en) Combinations comprising a beta-agonist and a further antidiabetic agent.
AU1540002A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
MXPA00003633A (es) Uso de tiazolidinodionas para el tratamiento de la hiperglucemia
MXPA00003634A (es) Uso de tiazolidinedionas para el tratamiento de hiperglicemia